Photo of Hagen Kennecke from ohsu.edu
Jul 10, 2024, 15:30
Hagen Kennecke: First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated colon cancer
Hagen Kennecke, Section chief and Chief Health Officer of the OHSU Knight-Legacy Health Cancer Collaborative, shared a post on X:
”First prospective trial to confirm benefit of adjuvant COX-2 in PIK3CA activated colon cancer, OS HR=0.4.
Patients are asking: do we recommend COX-2 for the 20% with mutation PIK3CA?
Need to do NGS for all stage III CRC.”
Source: Hagen Kennecke/X
Anthony F Shields
Ardaman Shergill
Benjamin Tan
cancer
Chao Ma
Charles S Fuchs
Colon cancer
Eileen M. O'Reilly
Felix Couture
Hagen Kennecke
James Knight
Jeffrey A Meyerhardt
Jonathan A Nowak
Juha Väyrynen
Kenji Fujiyoshi
Koichiro Haruki
Melissa Zhao
OncoDaily
Oncology
Pankaj Kumar
Philip Kuebler
Philip Philip
Qian Shi
Shrikant Mane
Shuji Ogino
Smitha Krishnamurthi
Tyler Twombly
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 22, 2024, 16:37
Oct 22, 2024, 16:31
Oct 22, 2024, 16:29
Oct 22, 2024, 16:22
Oct 22, 2024, 16:07
Oct 22, 2024, 16:07
Oct 22, 2024, 16:00
Oct 22, 2024, 15:58